Efficient production of HIV-1 virus-like particles from a mammalian expression vector requires the N-terminal capsid domain

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Jalaguier, Pascal ^a   Turcotte, Karine ^a   Danylo, Alexis ^a   Cantin, Réjean ^a   Tremblay, Michel J ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; EMBRYO; EXPRESSION VECTOR; GENE DELETION; GENE INSERTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STRUCTURAL GENE; STRUCTURE ACTIVITY RELATION; VIROGENESIS; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS EXPRESSION; VIRUS GENE; VIRUS LIKE AGENT; VIRUS PARTICLE; VIRUS RELEASE;

AMINO ACID SEQUENCE; ANIMALS; CAPSID; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENETIC VECTORS; HEK293 CELLS; HIV-1; HUMANS; MAMMALS; PROTEIN PRECURSORS; PROTEIN STRUCTURE, TERTIARY; VIRAL MATRIX PROTEINS; VIRION;

EID: 82355161915     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028314     Document Type: Article

References (67)

1. Deml L, Speth C, Dierich MP, Wolf H, Wagner R, (2005) Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 42: 259-277.
2. Doan LX, Li M, Chen C, Yao Q, (2005) Virus-like particles as HIV-1 vaccines. Rev Med Virol 15: 75-88.
3. Petry H, Goldmann C, Ast O, Luke W, (2003) The use of virus-like particles for gene transfer. Curr Opin Mol Ther 5: 524-528.
4. Furumoto H, Irahara M, (2002) Human papilloma virus (HPV) and cervical cancer. J Med Invest 49: 124-133.
5. Garland SM, Smith JS, (2010) Human papillomavirus vaccines: current status and future prospects. Drugs 70: 1079-1098.
6. Kwak K, Yemelyanova A, Roden RB, (2011) Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol 23: 244-251.
7. Cimarelli A, Darlix JL, (2002) Assembling the human immunodeficiency virus type 1. Cell Mol Life Sci 59: 1166-1184.
8. Adamson CS, Freed EO, (2007) Human immunodeficiency virus type 1 assembly, release, and maturation. Adv Pharmacol 55: 347-387.
9. Adamson CS, Jones IM, (2004) The molecular basis of HIV capsid assembly-five years of progress. Rev Med Virol 14: 107-121.
10. Ganser-Pornillos BK, Yeager M, Sundquist WI, (2008) The structural biology of HIV assembly. Curr Opin Struct Biol 18: 203-217.
11. Wills JW, Craven RC, (1991) Form, function, and use of retroviral gag proteins. AIDS 5: 639-654.
12. Gheysen D, Jacobs E, de Foresta F, Thiriart C, Francotte M, et al. (1989) Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59: 103-112.
13. Briggs JA, Simon MN, Gross I, Krausslich HG, Fuller SD, et al. (2004) The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 11: 672-675.
14. Paliard X, Liu Y, Wagner R, Wolf H, Baenziger J, et al. (2000) Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 16: 273-282.
15. Young KR, McBurney SP, Karkhanis LU, Ross TM, (2006) Virus-like particles: designing an effective AIDS vaccine. Methods 40: 98-117.
16. Chukkapalli V, Hogue IB, Boyko V, Hu WS, Ono A, (2008) Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane binding. J Virol 82: 2405-2417.
17. Zhou W, Parent LJ, Wills JW, Resh MD, (1994) Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol 68: 2556-2569.
18. Accola MA, Strack B, Göttlinger HG, (2000) Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J Virol 74: 5395-5402.
19. Borsetti A, Ohagen A, Göttlinger HG, (1998) The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. J Virol 72: 9313-9317.
20. Reil H, Bukovsky AA, Gelderblom HR, Göttlinger HG, (1998) Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J 17: 2699-2708.
21. Wang CT, Lai HY, Li JJ, (1998) Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release. J Virol 72: 7950-7959.
22. Freed EO, Orenstein JM, Buckler-White AJ, Martin MA, (1994) Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol 68: 5311-5320.
23. Göttlinger HG, Sodroski JG, Haseltine WA, (1989) Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 86: 5781-5785.
24. Dorfman T, Mammano F, Haseltine WA, Göttlinger HG, (1994) Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 68: 1689-1696.
25. Lodge R, Göttlinger H, Gabuzda D, Cohen EA, Lemay G, (1994) The intracytoplasmic domain of gp41 mediates polarized budding of human immunodeficiency virus type 1 in MDCK cells. J Virol 68: 4857-4861.
26. Berthet-Colominas C, Monaco S, Novelli A, Sibai G, Mallet F, et al. (1999) Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab. EMBO J 18: 1124-1136.
27. Worthylake DK, Wang H, Yoo S, Sundquist WI, Hill CP, (1999) Structures of the HIV-1 capsid protein dimerization domain at 2.6 A resolution. Acta Crystallogr D Biol Crystallogr 55: 85-92.
28. Chazal N, Carriere C, Gay B, Boulanger P, (1994) Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells. J Virol 68: 111-122.
29. Hong SS, Boulanger P, (1993) Assembly-defective point mutants of the human immunodeficiency virus type 1 Gag precursor phenotypically expressed in recombinant baculovirus-infected cells. J Virol 67: 2787-2798.
30. Trono D, Feinberg MB, Baltimore D, (1989) HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59: 113-120.
31. von Schwedler UK, Stray KM, Garrus JE, Sundquist WI, (2003) Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol 77: 5439-5450.
32. Joshi A, Nagashima K, Freed EO, (2006) Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation. J Virol 80: 7939-7951.
33. Ono A, Waheed AA, Joshi A, Freed EO, (2005) Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay. J Virol 79: 14131-14140.
34. Wright ER, Schooler JB, Ding HJ, Kieffer C, Fillmore C, et al. (2007) Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells. EMBO J 26: 2218-2226.
35. Abdurahman S, Hoglund S, Goobar-Larsson L, Vahlne A, (2004) Selected amino acid substitutions in the C-terminal region of human immunodeficiency virus type 1 capsid protein affect virus assembly and release. J Gen Virol 85: 2903-2913.
36. Liang C, Hu J, Russell RS, Roldan A, Kleiman L, et al. (2002) Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. J Virol 76: 11729-11737.
37. Liang C, Hu J, Whitney JB, Kleiman L, Wainberg MA, (2003) A structurally disordered region at the C terminus of capsid plays essential roles in multimerization and membrane binding of the gag protein of human immunodeficiency virus type 1. J Virol 77: 1772-1783.
38. Darlix JL, Godet J, Ivanyi-Nagy R, Fosse P, Mauffret O, et al. (2011) Flexible nature and specific functions of the HIV-1 nucleocapsid protein. J Mol Biol 410: 565-581.
39. Feng YX, Copeland TD, Henderson LE, Gorelick RJ, Bosche WJ, et al. (1996) HIV-1 nucleocapsid protein induces "maturation" of dimeric retroviral RNA in vitro. Proc Natl Acad Sci U S A 93: 7577-7581.
40. Muriaux D, De Rocquigny H, Roques BP, Paoletti J, (1996) NCp7 activates HIV-1Lai RNA dimerization by converting a transient loop-loop complex into a stable dimer. J Biol Chem 271: 33686-33692.
41. Khorchid A, Halwani R, Wainberg MA, Kleiman L, (2002) Role of RNA in facilitating Gag/Gag-Pol interaction. J Virol 76: 4131-4137.
42. Crist RM, Datta SA, Stephen AG, Soheilian F, Mirro J, et al. (2009) Assembly properties of human immunodeficiency virus type 1 Gag-leucine zipper chimeras: implications for retrovirus assembly. J Virol 83: 2216-2225.
43. Zhang Y, Qian H, Love Z, Barklis E, (1998) Analysis of the assembly function of the human immunodeficiency virus type 1 gag protein nucleocapsid domain. J Virol 72: 1782-1789.
44. Göttlinger HG, Dorfman T, Sodroski JG, Haseltine WA, (1991) Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A 88: 3195-3199.
45. VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, et al. (2001) Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A 98: 7724-7729.
46. Bieniasz PD, (2009) The cell biology of HIV-1 virion genesis. Cell Host Microbe 5: 550-558.
47. Strack B, Calistri A, Craig S, Popova E, Göttlinger HG, (2003) AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114: 689-699.
48. Ott DE, Coren LV, Gagliardi TD, Nagashima K, (2005) Heterologous late-domain sequences have various abilities to promote budding of human immunodeficiency virus type 1. J Virol 79: 9038-9045.
49. Strack B, Calistri A, Göttlinger HG, (2002) Late assembly domain function can exhibit context dependence and involves ubiquitin residues implicated in endocytosis. J Virol 76: 5472-5479.
50. Wada K, Aota S, Tsuchiya R, Ishibashi F, Gojobori T, et al. (1990) Codon usage tabulated from the GenBank genetic sequence data. Nucleic Acids Res 18 Suppl pp. 2367-2411.
51. Ako-Adjei D, Johnson MC, Vogt VM, (2005) The retroviral capsid domain dictates virion size, morphology, and coassembly of gag into virus-like particles. J Virol 79: 13463-13472.
52. Ono A, (2010) HIV-1 assembly at the plasma membrane. Vaccine 28 (Suppl 2): B55-59.
53. Ono A, (2007) Subcellular locations at which HIV-1 assembles. Uirusu 57: 9-18.
54. Ono A, Ablan SD, Lockett SJ, Nagashima K, Freed EO, (2004) Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc Natl Acad Sci U S A 101: 14889-14894.
55. Bryant M, Ratner L, (1990) Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A 87: 523-527.
56. Demirov DG, Freed EO, (2004) Retrovirus budding. Virus Res 106: 87-102.
57. Hansen M, Jelinek L, Whiting S, Barklis E, (1990) Transport and assembly of gag proteins into Moloney murine leukemia virus. J Virol 64: 5306-5316.
58. Jones TA, Blaug G, Hansen M, Barklis E, (1990) Assembly of gag-beta-galactosidase proteins into retrovirus particles. J Virol 64: 2265-2279.
59. Ono A, Orenstein JM, Freed EO, (2000) Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J Virol 74: 2855-2866.
60. Sandefur S, Varthakavi V, Spearman P, (1998) The I domain is required for efficient plasma membrane binding of human immunodeficiency virus type 1 Pr55Gag. J Virol 72: 2723-2732.
61. Ono A, Freed EO, (2004) Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol 78: 1552-1563.
62. Kiernan RE, Ono A, Englund G, Freed EO, (1998) Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol 72: 4116-4126.
63. Yuan X, Yu X, Lee TH, Essex M, (1993) Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol 67: 6387-6394.
64. Ganser-Pornillos BK, Cheng A, Yeager M, (2007) Structure of full-length HIV-1 CA: a model for the mature capsid lattice. Cell 131: 70-79.
65. Roy BB, Hu J, Guo X, Russell RS, Guo F, et al. (2006) Association of RNA helicase a with human immunodeficiency virus type 1 particles. J Biol Chem 281: 12625-12635.
66. Cantin R, Fortin JF, Lamontagne G, Tremblay M, (1997) The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virol 71: 1922-1930.
67. Fortin JF, Cantin R, Lamontagne G, Tremblay M, (1997) Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 71: 3588-3596.